Parkinson’s, Alzheimer’s or ALS: Why Neurodegenerative Diseases Need Different Care Plans

Maria keeps three folders on her kitchen counter. One is for her father, whose right hand began trembling two winters ago. One is for her mother-in-law, who now asks the same question about the mail four times before lunch. The third belongs to a neighbor whose voice turned slurred and whose grip weakened over a single summer. Three people, three diagnoses, and one recurring frustration: every specialist gives a different set of instructions, and nobody seems to agree on a single roadmap.

That frustration is the honest starting point for understanding why neurodegenerative diseases need different care plans. The word ‘neurodegenerative’ groups these conditions together because nerve cells die over time in all of them. The grouping is real, but it hides more than it reveals.

A tremor, a lost word and a weak hand are not three versions of the same problem. They are three different circuits failing, each on its own schedule, and each demanding its own kind of attention.

What do neurodegenerative diseases share, and why do they still need different care plans?

A neurodegenerative disease is any condition in which nerve cells in the brain or spinal cord gradually stop working and die, and are not replaced. That single definition covers dozens of disorders. The three in this article are the ones most families encounter. The World Health Organization estimates that more than 55 million people live with dementia worldwide, with Alzheimer’s disease accounting for roughly 60 to 70 percent of cases, and that more than 8.5 million people were living with Parkinson’s disease in a recent global count.

The shared features are genuine. In all three, the process is progressive rather than sudden, which separates them from a stroke or a head injury. In all three, abnormal proteins accumulate inside or around nerve cells: alpha-synuclein in Parkinson’s, amyloid and tau in Alzheimer’s, and most often a protein called TDP-43 in ALS. And in all three, no current treatment reverses the underlying cell loss. Treatment manages symptoms, supports function and, in some cases, slows the pace.

Here is where the grouping stops being useful. A house can fail through its wiring, its plumbing or its foundation. All three are ‘structural problems,’ yet nobody would send the same contractor with the same toolkit. Parkinson’s disease strips out cells that make dopamine, the chemical messenger that smooths movement. Alzheimer’s erodes the networks that form and retrieve memories. ALS destroys motor neurons, the nerve cells that carry commands from brain to muscle. Different cells, different symptoms, different urgencies.

That is why a care plan built around ‘neurodegeneration’ in general tends to serve nobody well. A good plan starts from what is actually being lost, how quickly, and what the person in front of the team most wants to protect.

What are the different categories of neurodegenerative diseases?

Clinicians sort these disorders in two overlapping ways: by what fails first, and by which protein misbehaves. The first system is the one that shapes day-to-day care.

• Cognitive disorders primarily affect memory, language, judgment or behavior. Alzheimer’s disease is the most common. Frontotemporal dementia, which strikes personality and language earlier and often at a younger age, and dementia with Lewy bodies, which mixes memory problems with Parkinson-like movement and visual hallucinations, sit in this group too.
• Movement disorders primarily affect how the body moves. Parkinson’s disease is the best known. Huntington’s disease, which is inherited and causes involuntary dance-like movements alongside cognitive change, and rarer conditions such as multiple system atrophy and progressive supranuclear palsy belong here.
• Motor neuron diseases attack the nerve cells that drive voluntary muscles while typically sparing sensation. ALS, also called motor neurone disease in the UK, is the most common adult form. Spinal muscular atrophy is a childhood-onset relative.

The second system groups diseases by their protein signature: amyloid and tau in Alzheimer’s, alpha-synuclein in Parkinson’s and Lewy body dementia, TDP-43 in most ALS. Researchers care about this because a treatment aimed at one protein is unlikely to help a disease driven by another. Families feel it in a different way: it explains why a memory drug does nothing for a tremor.

The categories leak into one another. Many people with Parkinson’s develop thinking problems after years of disease. A minority of people with ALS develop a frontotemporal-type dementia. That overlap is one more reason plans are written for a person, reviewed regularly, and never copied from a category label. MedlinePlus keeps an accessible overview of the full range of degenerative nerve diseases for readers who want the wider map.

How each disease actually works: three patterns of nerve loss

Understanding the mechanism is not academic. It predicts which symptoms arrive first, which treatments can help, and which cannot.

Parkinson’s disease begins in a small, dark-pigmented region deep in the brain called the substantia nigra, whose cells produce dopamine. By the time a tremor or stiffness is obvious enough for a diagnosis, a large share of those cells has already been lost. The brain compensates for years before symptoms surface, which is why the disease seems to appear from nowhere. Dopamine loss slows movement, shrinks handwriting, softens the voice and stiffens the face. Because the chemical shortfall is specific, replacing dopamine’s signal can restore a surprising amount of function, at least for a time.

Alzheimer’s disease works differently. Clumps of amyloid protein collect between cells, and twisted strands of tau build up inside them. The damage typically begins in the hippocampus, the seahorse-shaped structure that files new memories, then spreads outward to regions handling language, spatial sense and judgment. There is no single chemical to replace. Drugs can nudge remaining cells to communicate more efficiently, but the loss is of networks, not one messenger.

ALS attacks two sets of motor neurons at once: those running from the brain’s surface down the spinal cord, and those running from the spinal cord out to the muscles. As these die, muscles weaken, twitch and waste. Thinking, sight, hearing and bladder control are usually preserved, though some people develop changes in thinking or behavior. Breathing and swallowing rely on muscles too, which is why ALS care so quickly becomes about lungs and nutrition.

Three mechanisms, three trajectories. Parkinson’s typically unfolds over one to two decades. Alzheimer’s usually progresses over years. ALS, in most people, progresses over a few years. Pace alone reshapes what a care plan must prioritize and how often it must be revisited.

Parkinson's care plan: replacing dopamine and protecting movement

The NHS notes that Parkinson’s disease affects around 1 in 500 people, most of them over 50. Its care plan is built around a chemical fact: the brain is short of dopamine, and that shortage can be partially corrected.

Levodopa, the mainstay medication, is a building block the brain converts into dopamine. People commonly notice meaningful improvement in stiffness and slowness once it is started, and for many that benefit lasts years. Over time the response often becomes less smooth, with ‘wearing off’ before the next dose and, in some people, involuntary writhing movements. Timing relative to meals matters because dietary protein competes with levodopa for absorption; the prescribing clinician sets that schedule, and it usually changes as the disease evolves. Other drug classes, such as dopamine agonists that mimic dopamine at its receptors, and enzyme inhibitors that slow dopamine’s breakdown, are combined or substituted according to the person’s age, symptoms and side effects.

Medication is only half the plan. Non-motor symptoms are the part families are least prepared for: constipation, disturbed sleep, low mood, reduced sense of smell, blood pressure drops on standing, and later, thinking changes. Each has its own management pathway, and several respond poorly to dopamine drugs, which is why a neurologist alone is rarely enough.

Exercise carries unusually strong evidence here. Structured physical activity, including balance and resistance training, is associated with better mobility and fewer falls, and it is one of the few interventions a person controls directly. Physiotherapists teach cueing strategies for freezing, occupational therapists adapt the home, and speech and language therapists address the soft voice and swallowing changes that arrive quietly.

For a minority with troublesome fluctuations, deep brain stimulation (a surgically implanted device that delivers electrical pulses to targeted brain regions) is considered. Who qualifies is discussed later, but the shape of the plan is clear: restore a missing chemical, keep the body moving, and watch for everything dopamine does not fix.

Alzheimer's care plan: memory, safety and the person alongside

Alzheimer’s care has no single missing chemical to restore, so its plan leans on three pillars: medicines that support remaining brain networks, an environment that compensates for what is lost, and sustained attention to the caregiver.

Two long-established drug classes help some people modestly. Cholinesterase inhibitors slow the breakdown of acetylcholine, a messenger involved in attention and memory that Alzheimer’s depletes. Memantine dampens excess activity of glutamate, another messenger that can overstimulate weakened cells. Neither halts the disease; the evidence shows temporary stabilization or slowed decline in some people rather than reversal.

A newer class, anti-amyloid monoclonal antibodies, is designed to clear amyloid plaques from the brain. Trials in early-stage disease reported a modest slowing of decline compared with placebo, alongside a risk of brain swelling or small bleeds visible on MRI scans, a side effect called ARIA. Eligibility requires confirmed amyloid on testing, an early stage of illness, and regular imaging. Whether the benefit justifies the monitoring burden and risk is a decision made person by person with the prescribing team.

The environmental work often matters as much. Predictable routines, labeled cupboards, medication organizers, a stove that shuts off automatically, and a plan for wandering reduce daily crises. Hearing aids and glasses that actually fit remove a surprising amount of confusion. Early conversations about driving, finances and legal authority protect autonomy precisely because they happen while the person can still voice preferences.

Infections, dehydration, pain and new medicines can trigger sudden worsening called delirium, which is treatable when caught. Families are taught to recognize it because the difference between ‘the disease got worse’ and ‘there is a bladder infection’ is enormous.

Caregiver health is written into the plan deliberately. Respite, support groups and screening for caregiver depression are not extras; the WHO identifies caregiver strain as a core component of the dementia burden.

ALS care plan: breathing, swallowing and the question of pace

ALS runs faster than the other two diseases, and its care plan is shaped by that speed. The NHS notes that life expectancy after symptoms begin is commonly two to five years, that some people live for ten years or more, and that the pattern varies widely. Because time is compressed, the plan front-loads decisions that in Alzheimer’s or Parkinson’s might wait years.

One disease-modifying drug, riluzole, reduces the release of glutamate, a messenger that in excess may hasten motor neuron death. The NHS describes its effect as a modest extension of survival, typically measured in months rather than years. Other agents are approved in some countries with limited evidence; the treating neurologist explains what each is expected, and not expected, to do.

Breathing is the plan’s center of gravity. Weakness of the diaphragm arrives silently, so lung function is measured at regular intervals. When tests show decline, non-invasive ventilation, a mask connected to a small machine that supports breathing, especially at night, is offered. Evidence links it to better sleep, fewer morning headaches and longer survival in people who tolerate it.

Swallowing follows a similar logic. Weight loss accelerates decline, so dietitians intervene early, and a feeding tube placed through the abdominal wall (a gastrostomy) is usually discussed before breathing becomes too weak for the procedure to be safe. Speech therapists introduce communication devices, including eye-tracking systems, before speech is lost, so the technology is familiar when needed.

Multidisciplinary ALS clinics, where neurology, respiratory, nutrition, therapy and palliative teams see the person on the same day, are the standard model. Studies associate this coordinated approach with better quality of life. Advance care planning, meaning documented preferences about ventilation, feeding and end-of-life care, begins early and is revisited as the person’s wishes evolve.

What are the treatment options for neurodegenerative diseases? A side-by-side view

Placing the three plans next to each other shows why ‘treatment for neurodegenerative disease’ is not a meaningful phrase. The tools overlap far less than the label suggests.

Element of care	Parkinson’s disease	Alzheimer’s disease	ALS
What is lost	Dopamine-producing cells controlling movement	Memory and thinking networks	Motor neurons driving voluntary muscles
Main medicine classes	Levodopa, dopamine agonists, enzyme inhibitors	Cholinesterase inhibitors, memantine, anti-amyloid antibodies in early disease	Riluzole; symptom-directed drugs for cramps, saliva, mood
What medicines can do	Substantially improve movement for years	Modestly slow or stabilize decline in some	Modestly slow progression; ease symptoms
Central non-drug work	Exercise, physiotherapy, fall prevention	Routine, home safety, caregiver support	Breathing support, nutrition, communication aids
Procedures sometimes offered	Deep brain stimulation	MRI monitoring with antibody treatment	Gastrostomy, non-invasive ventilation
Typical course	One to two decades	Several years	A few years, highly variable
Palliative planning	Gradual, often in later stages	Early, while capacity is intact	From diagnosis

Two columns deserve a second look. The ‘what medicines can do’ row is the most misunderstood. Parkinson’s medication often transforms function; Alzheimer’s medication rarely does; ALS medication buys time and comfort. Families who expect the same magnitude of effect across all three are set up for disappointment or false hope.

The ‘palliative planning’ row is the most neglected. It is not about the end of life. It is about matching the timing of difficult conversations to the pace of the disease, so that choices are made by the person rather than for them.

Who is usually offered which treatment, and who is usually asked to wait

Every treatment on the table above has eligibility criteria, and the reasons behind them are worth knowing. They are not rationing for its own sake; they reflect where the evidence shows benefit and where it shows risk.

Deep brain stimulation in Parkinson’s is generally considered for people whose movement still responds well to levodopa but who suffer disabling fluctuations or dyskinesias despite optimized medication. People with significant dementia, poorly controlled psychiatric symptoms, or symptoms that never responded to levodopa are usually not offered it, because the device tends to help only what the drug helps. Someone newly diagnosed with well-controlled symptoms is typically asked to wait, not because surgery is dangerous in principle but because the trade-off is not yet favorable.

Anti-amyloid antibodies in Alzheimer’s are restricted to early-stage disease with confirmed amyloid on a scan or spinal fluid test. People in moderate or advanced stages, those with certain genetic profiles that raise the risk of brain swelling, and those on some blood-thinning medicines are commonly excluded because the trials either did not include them or found higher harm. Regular MRI scanning is a condition of treatment, and a person unable to undergo MRI is generally not a candidate.

Gastrostomy and non-invasive ventilation in ALS follow the opposite logic: teams prefer to act earlier rather than later. A feeding tube is usually recommended while breathing function is still adequate, because sedation becomes riskier as the diaphragm weakens. Waiting is discouraged; some people nonetheless choose to wait or decline, and that choice is respected.

Clinical trials are an option across all three diseases, each with its own entry criteria. A neurologist can explain which trials are enrolling and whether the person’s stage fits.

The decision in every case rests with the treating team and the person, weighing the specific evidence against personal priorities. Criteria change as research matures, so a ‘not yet’ is often literally that.

What the first weeks after a diagnosis usually look like

The days after a diagnosis feel like a storm of appointments, and it helps to know what each one is for. The pattern differs by disease, but the architecture is similar: establish a baseline, assemble a team, start what needs starting, and set a review date.

For Parkinson’s, the neurologist typically records a detailed movement examination so future change can be measured. Medication may be started at once or deferred depending on how much symptoms interfere with life; both approaches are standard, and the choice is individualized. A referral to physiotherapy usually follows early, along with advice on driving regulations, which vary by region.

For Alzheimer’s, the first weeks often involve completing tests that were pending: blood work to exclude reversible contributors such as thyroid or vitamin B12 problems, brain imaging, and sometimes more detailed cognitive testing. A discussion about medication follows, alongside the harder conversations about legal authority, finances and future wishes. These are raised early on purpose, while the person can lead them.

For ALS, the pace is quicker. Baseline breathing tests and weight are recorded, a multidisciplinary clinic appointment is scheduled, and disease-modifying treatment is discussed. Referral to palliative care commonly happens at this stage, which can feel alarming; its purpose is explained in the next section.

Across all three, a realistic expectation is that the first follow-up occurs within weeks to a few months, and that the interval is set by the team based on how quickly things are changing. Families are usually encouraged to keep a simple diary of symptoms, medication times and side effects, because the person’s own record is often more informative than a fifteen-minute recollection in clinic.

Information overload is normal. Writing down questions between visits, and bringing a second person to appointments, are the two habits clinicians most often recommend.

What is neuropalliative care, and when should it start?

Palliative care is specialized support focused on relieving symptoms and stress, improving quality of life, and helping people make decisions that match their values. It is delivered alongside disease treatment, not instead of it. Neuropalliative care applies that discipline to neurological conditions, whose symptom patterns and decision points differ from cancer, where palliative medicine first developed.

The WHO explicitly lists palliative care among the essential components of dementia care, and the same principle runs through guidance for Parkinson’s and ALS. The reason is practical. These diseases produce symptoms that neurologists alone are not always positioned to manage well: pain from rigidity, breathlessness, drooling, anxiety, constipation, sleep disruption and the emotional weight of watching function slip. Palliative teams are trained in exactly these problems.

The second function is advance care planning. This means documenting, in advance, what a person would and would not want if they became unable to speak for themselves, and naming someone to speak on their behalf. In ALS, questions about ventilation and feeding are raised early because they will arise while the person is still fully able to decide. In Alzheimer’s, the conversation is time-sensitive in a different way: it must happen before the disease removes the ability to weigh options. In Parkinson’s, it is often prompted by a hospital admission, when the risk of missed medication doses and delirium becomes concrete.

Timing is the thing families most often get wrong. Referral does not mean death is near. Many people see palliative teams for years while continuing every active treatment. Evidence from multiple disease settings links earlier involvement with better symptom control and less unwanted aggressive intervention at the end of life. The care team decides when a referral is appropriate; asking about it early costs nothing and often reframes the entire experience.

Are there good supplements for neurodegenerative diseases? What the evidence shows

This is among the most-searched questions in the field, and the honest answer is unsatisfying: for prevention or treatment of Parkinson’s, Alzheimer’s or ALS, no over-the-counter supplement has convincing evidence of benefit in well-designed trials.

Vitamin E has been studied more than most because it is an antioxidant and oxidative stress is implicated in nerve cell damage. The NIH Office of Dietary Supplements summarizes the trials as mixed: some suggested slower functional decline in people already diagnosed with Alzheimer’s, others found no effect, and large trials in healthy older adults showed no protection against cognitive decline. The same fact sheet flags a real safety point: high intakes of vitamin E can increase bleeding risk, particularly in people taking anticoagulants.

Ginkgo biloba was tested in a large, long-running trial in older adults and did not reduce the incidence of dementia. Omega-3 fatty acids, popular for ‘brain health,’ have not shown clear benefit for established Alzheimer’s in randomized trials, though eating fish as part of an overall dietary pattern is associated with lower dementia risk in observational studies, which cannot prove cause. Coenzyme Q10 and creatine were tested in Parkinson’s and ALS respectively and did not slow progression.

Where supplements do matter is deficiency. Low vitamin B12 can itself cause memory problems and nerve damage, and correcting a documented deficiency is standard medical care, guided by blood tests rather than guesswork. Vitamin D levels are commonly checked in people with reduced mobility or sun exposure. Both are prescribed and monitored by the treating clinician.

Two cautions carry across everything. Supplements can interact with prescribed medicines; St John’s wort, for example, alters the metabolism of many drugs. And money spent on unproven products is money not spent on physiotherapy, hearing aids or respite, all of which have better evidence. Anyone considering a supplement should list it for their team.

What people often get wrong about neurodegenerative diseases and their care plans

Misconceptions shape decisions, sometimes for years. These are the ones clinicians correct most often.

‘They are all forms of the same thing.’ They share a mechanism category, not a treatment. Parkinson’s medication improves movement and does nothing for memory loss caused by Alzheimer’s; Alzheimer’s medication does nothing for a tremor. Care plans diverge because the diseases do.

‘Dementia and Alzheimer’s are the same word.’ Dementia describes a syndrome of declining thinking severe enough to affect daily life. Alzheimer’s is its most common cause, but vascular disease, Lewy bodies and frontotemporal degeneration cause dementia too, and their management differs. Lewy body dementia, in particular, involves sensitivity to certain antipsychotic drugs, which is one reason the exact cause matters.

‘Parkinson’s is just a tremor.’ Roughly a quarter of people with Parkinson’s never develop a prominent tremor, and the non-motor symptoms often affect quality of life more than the movement ones.

‘ALS takes the mind too.’ In most people it does not; awareness, personality and senses remain intact. A minority develop cognitive or behavioral change, which is screened for, but the default assumption of mental decline is wrong and isolating.

‘Delay levodopa to save it for later.’ This belief persists despite evidence that the fluctuations which develop over years track with disease progression rather than with how early treatment began. Timing is an individual decision, but ‘saving’ the drug is not supported.

‘Palliative care means the team has given up.’ Palliative involvement runs alongside active treatment, often for years, and focuses on living better rather than dying sooner.

‘Nothing can be done, so why bother with appointments?’ Cell loss cannot yet be reversed, but falls, weight loss, infections, depression, sleep problems and caregiver collapse can all be prevented or treated, and each of them changes the trajectory more than most people expect.

Questions to ask your care team

Good questions do more than gather facts; they signal to the team what matters to you and shape the plan accordingly. The list below is deliberately different for each disease, because the decision points are different.

For anyone, at any stage:

• Which of my symptoms is this treatment expected to help, and which will it not touch?
• What does the evidence actually show about how much it helps, and for how long?
• Who coordinates my care between specialists, and how do I reach them between appointments?
• When is the right time to talk about advance care planning, and can palliative care be involved now?
• Are there clinical trials I might be eligible for?

If the diagnosis is Parkinson’s:

• How should I time medication around meals, and what should I do if a dose is missed?
• Which non-motor symptoms should I watch for, and who manages them?
• What kind and amount of exercise does the team recommend for me specifically?
• At what point, if ever, would deep brain stimulation be considered?

If the diagnosis is Alzheimer’s:

• Have reversible contributors such as B12, thyroid or medication side effects been ruled out?
• Am I a candidate for any disease-modifying treatment, and what monitoring would it involve?
• What legal and financial steps should happen while I can still lead them?
• What support exists for my caregiver, and how do we recognize delirium?

If the diagnosis is ALS:

• How often will my breathing and weight be checked, and what results would prompt action?
• When should we discuss a feeding tube and non-invasive ventilation so the decision is mine?
• Which communication tools should I learn now, before I need them?

Bring the list written down, and ask the team to note the answers in your record so they are available to everyone involved.

When to call your doctor

Slow change is the nature of these diseases. Sudden change is not, and it usually means something treatable has been added on top. The following signs warrant same-day contact with the care team, or emergency services where breathing or consciousness is affected.

Across all three conditions:

• A sudden increase in confusion, drowsiness or agitation over hours to days, which often signals delirium from infection, dehydration, pain or a new medicine.
• A fall with head injury, or any fall followed by new weakness, severe pain or inability to bear weight.
• Fever with cough, painful urination or a wound that looks infected.
• Signs of a stroke: sudden facial droop, one-sided weakness, or trouble speaking, which require emergency services immediately.
• Thoughts of self-harm in the person or a caregiver at breaking point.

Parkinson’s disease: sudden inability to move or severe stiffness after missed medication or a hospital stay; new hallucinations or paranoia; fainting or near-fainting on standing; choking on food or fluids.

Alzheimer’s disease: wandering from home or getting lost; refusing food and drink for more than a day; a caregiver who feels unable to continue safely; new incontinence appearing abruptly.

ALS: new or worsening breathlessness, especially when lying flat; morning headaches or excessive daytime sleepiness, which can indicate overnight breathing failure; choking episodes or a chest infection; rapid weight loss; inability to clear secretions.

Many people hesitate to call because they assume decline is ‘expected.’ Clinicians would rather hear about a change that turns out to be nothing than miss an infection, a fracture or a breathing problem that could have been treated. The care team, not the family, decides what is expected; the family’s job is to report what is new.

Frequently asked questions

What are the treatment options for neurodegenerative diseases?

Treatment depends entirely on which disease is present. Parkinson’s is managed mainly with dopamine-replacing medicines, exercise and physiotherapy, with deep brain stimulation for selected people. Alzheimer’s uses cholinesterase inhibitors, memantine and, in early disease, anti-amyloid antibodies, alongside home safety and caregiver support. ALS relies on riluzole, breathing support, nutrition and communication aids. All three benefit from palliative care and advance planning.

What are the top 10 neurological diseases?

Lists vary by how burden is measured, but the conditions most often cited include stroke, migraine, epilepsy, Alzheimer’s and other dementias, Parkinson’s disease, multiple sclerosis, ALS, peripheral neuropathy, traumatic brain injury and brain tumors. Only some of these are neurodegenerative; stroke and injury are sudden events, while dementia, Parkinson’s and ALS involve progressive nerve cell loss over time.

What are the different categories of neurodegenerative diseases?

Clinicians group them by what fails first: cognitive disorders such as Alzheimer’s, frontotemporal dementia and Lewy body dementia; movement disorders such as Parkinson’s and Huntington’s; and motor neuron diseases such as ALS. A second system groups them by the abnormal protein involved, including amyloid and tau, alpha-synuclein, and TDP-43. The categories overlap, and many people develop features of more than one.

What are some good supplements for neurodegenerative diseases?

No supplement has convincing evidence for preventing or treating Parkinson’s, Alzheimer’s or ALS in well-designed trials. Vitamin E results are mixed and high intakes raise bleeding risk; ginkgo did not prevent dementia in a large trial; omega-3 has not helped established Alzheimer’s. Correcting a documented vitamin B12 or D deficiency is legitimate medical care, guided by blood tests and the treating clinician.

Can Parkinson's disease turn into Alzheimer's?

Not exactly, though many people with Parkinson’s develop thinking problems after years of illness. This is usually Parkinson’s disease dementia, driven by the same alpha-synuclein protein rather than the amyloid and tau of Alzheimer’s. The two can coexist in older adults. Because management differs, including sensitivity to certain drugs, the neurologist will want to clarify which process is responsible.

Is ALS the same as Parkinson's disease?

No. ALS destroys motor neurons that carry commands to muscles, causing weakness and wasting while usually sparing thinking and sensation. Parkinson’s destroys dopamine-producing cells that smooth movement, causing tremor, stiffness and slowness without weakness. ALS typically progresses over a few years; Parkinson’s over one to two decades. Their medicines, monitoring and care priorities differ accordingly.

How fast does each disease progress?

Pace varies widely between individuals, but typical patterns differ. Parkinson’s usually unfolds over one to two decades. Alzheimer’s generally progresses over several years. The NHS notes that life expectancy after ALS symptoms begin is commonly two to five years, with some people living ten years or more. The treating team can describe the likely trajectory for a specific person.

What is advance care planning and when should it start?

Advance care planning means recording, in advance, the medical care a person would and would not want if unable to speak for themselves, and naming someone to represent them. In ALS it usually begins at diagnosis. In Alzheimer’s it is time-sensitive because capacity declines. In Parkinson’s it is often prompted by a hospital admission. Earlier is better in all three.

Does exercise help neurodegenerative diseases?

Evidence is strongest in Parkinson’s, where structured exercise including balance and resistance training is associated with better mobility and fewer falls. In Alzheimer’s, physical activity is linked to better mood and function, though it does not reverse memory loss. In ALS, gentle, supervised exercise may maintain function without hastening decline. A physiotherapist tailors the program to the person and stage.

Why do people with these conditions see so many different specialists?

Because each disease affects multiple body systems and no single specialist covers them all. A neurologist manages diagnosis and medication, physiotherapists and occupational therapists protect function, speech therapists handle voice and swallowing, dietitians manage nutrition, respiratory teams support breathing in ALS, and palliative teams address symptoms and planning. Multidisciplinary clinics exist to bring these together on one day.

References

• World Health Organization – Dementia fact sheet
• World Health Organization – Parkinson disease fact sheet
• NHS – Motor neurone disease
• NHS – Parkinson's disease

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.